Sophie Archer, Phillip M Brailey, Minjung Song, Phillip D Bartlett, Ines Figueiredo, Bora Gurel, Christina Guo, Verena Brucklacher-Waldert, H Lorraine Thompson, Jude Akinwale, Samantha E Boyle, Christine Rossant, Neil R Birkett, Julia Pizzey, Mark Maginn, James Legg, Richard Williams, Colette M Johnston, Philip Bland-Ward, Johann S de Bono, Andrew J Pierce
PURPOSE: CD137 is a T- and NK-cell costimulatory receptor involved in consolidating immunologic responses. The potent CD137 agonist urelumab has shown clinical promise as a cancer immunotherapeutic but development has been hampered by on-target off-tumor toxicities. A CD137 agonist targeted to the prostate-specific membrane antigen (PSMA), frequently and highly expressed on castration-resistant metastatic prostate cancer (mCRPC) tumor cells, could bring effective immunotherapy to this immunologically challenging to address disease...
April 9, 2024: Clinical Cancer Research